Why Ultragenyx Pharmaceutical Stock Is Bouncing Back Today

Core Viewpoint - Ultragenyx Pharmaceutical experienced a significant decline in share price, dropping over 42%, but some investors remain optimistic about its potential in developing treatments for rare diseases, leading to a partial recovery with shares up 13.2% as of 2:51 p.m. ET [1] Summary by Sections - Analyst Outlook - Wells Fargo analyst Benjamin Burnett maintains an overweight rating on Ultragenyx, reducing the price target from $65 to $45, which still suggests an upside of over 128% from the recent closing price of $19.72 [3][5] - FDA Feedback and Study Results - Burnett highlighted the favorable risk-reward profile of Ultragenyx stock, anticipating feedback from the FDA regarding setrusumab, which showed statistically significant results in bone mineral density during Phase 3 studies, despite failing to meet primary endpoints [4][5] - Investment Considerations - While Burnett's positive sentiment is noted, Ultragenyx should be considered only by investors with higher risk tolerances, as the company continues to incur net losses despite generating revenue from product sales [6][8]